TBTalamanchi Balakrishna

Talamanchi Balakrishna

*This is an algorithmically generated author record based on publicly available information.

Talamanchi Balakrishna has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Neuroprotective Potential of Nutraceuticals in Managing Neurodegenerative Disorders

    by Balakrishna Talamanchi

    The Asian Journal of Pharmaceutics is a peer-reviewed open-access medical journal published by Medknow Publications on behalf of the B.R. Nahata Smriti Sansthan (Memorial Trust) (Mandsaur, India). Articles address topics in pharmaceutics, biopharmaceutics, pharmaceutical chemistry, pharmacognosy, pharmacology, pharmaceutical analysis, pharmacy practice, and clinical and hospital pharmacy.

  • Open Access

    Design and Optimizing Lansoprazole Solubility through Nanocrystallization: A Dual Polymer Approach

    by T. Balakrishna

    The Asian Journal of Pharmaceutics is a peer-reviewed open-access medical journal published by Medknow Publications on behalf of the B.R. Nahata Smriti Sansthan (Memorial Trust) (Mandsaur, India). Articles address topics in pharmaceutics, biopharmaceutics, pharmaceutical chemistry, pharmacognosy, pharmacology, pharmaceutical analysis, pharmacy practice, and clinical and hospital pharmacy.

  • Artificial Intelligence and Machine Learning in Drug Discovery

    by Krishnaveni Manubolu, Talamanchi Balakrishna, Gorintla Sai Supraja, Venkateswara Rao Javvaji, Shaik Rasheed, Kishore Kumar Kadimpati

    Artificial intelligence (AI) and machine learning (ML) in drug discovery is a new age of pharmaceutical research that presents an outstanding improvement in drug development procedures regarding efficiency and accuracy. Long delays and unreasonably high failure rates have often been connected with traditional drug development techniques. Alternatively, AI and ML technologies offer very powerful tools that can accelerate and upgrade most steps of drug discovery, from the identification of an initial target to the final optimization of medication. For instance, how AI and ML are transforming drug discovery is found in this article. This paper explores essential developments such as deep learning algorithmic analysis of large datasets, predictive modeling that predicts the interaction between drugs and their effectiveness, and data-driven insights to utilize in establishing every stage of the development process. Discussion is also given over the difficulties concerning AI and ML, including issues in algorithmic biases, quality of data, and the requirement to have critical validation. This chapter gives a comprehensive overview of how AI and ML are changing pharmaceutical research, which promises more effective and customized methods of drug discovery.

  • Interdisciplinary Perspectives in Drug Discovery

    by Krishnaveni Manubolu, Talamanchi Balakrishna, Chandika Naga Veera Venkata Pravallika, K. Ravi Shankar, Lakshman Kumar Dogiparthi, Sreenivasulu Munna

    Multidisciplinary approaches, known as combined discursive approaches, also are a cooperation method by which the intersecting science and technique of diverse scientific fields are applied in an attempt to boost medication discovery. This multidisciplinary approach constitutes a systems approach in that it addresses the scientific challenges of moving into new treatments in chemistry, biology, pharmacology, computational science, mathematics and engineering and regulatory science. Creating, refining chemicals for chemistry; and the study of biological targets and methods of action for biology. Drug behavior and pharmacologists test drug interactions and effects are modelled and simulated by computational scientists. Robust data analysis renew themselves to mathematical statistical techniques, while engineering leads to the creation of novel, creative drug delivery devices. Expert advice from regulatory scientists and ethicists on how to stay on the state of safety and ethics. Diverse viewpoints of multidisciplinary cooperation promotes new pharmaceutical emergence, enhances drug safety and efficacy characteristics, and enables shorter drug development, ultimately producing superior therapeutic results.

  • Regulatory Considerations and Ethical Issues

    by Talamanchi Balakrishna, Cheruku Jigeesha Naga Durga Sai Pa Pranitha, Raveesha Peeriga, Venkateswara Rao Javvaji, Avisa Indira, Yadlapalli Vamsi Abhiram

    It is noteworthy that regulatory science affiliates law and politics with science, and is indispensable to preserve and ensure the understanding of the population health, as well as the guaranteed effectiveness and safety of a procedure or a product. The policy areas include developing technology, food and agriculture, medicine and medical devices and the environment. Opportunities and problems are: rapid technological growth, effective market globalization, and advanced scientific development. This chapter addresses the present and future contingents of Regulatory Aspects 20 in the Pharmaceutical World. A case of challenges involved and perspectives drawn paint the picture of the development of the pharmaceutical control in history. The chapter explores new methodological approaches and a technology affecting the regulation processes, identifies further regulation trends, and provides recommendations for the future of pharmaceutical regulations.

  • Introduction to Drug Discovery

    by Krishnaveni Manubolu, Talamanchi Balakrishna, Deevi Gouri Naga Venkata Gayathri, Janga Karthik Reddy, Nagasen Dasari, Sidagam Lokesh Kumar

    Drug discovery is a huge and complex process incorporating diverse disciplines for the discovery of new therapeutic opportunities for many different diseases. This report traces the history of drug discovery and describes the major stages of the discovery process as target identification, hit identification, lead optimization, and preclinical testing. It further includes recent advancements, such as high throughput screening and computer-aided drug design, that have revitalized the art by accelerating the discovery process and making it much more accurate. Innovation is essential to drug discovery because it typically produces new processes and tools that overcome the limitations of their forerunners. The research delves into modern drug discovery in relation to biotechnology, ethics connected with such ventures, and the regulatory aspects in terms of safety and efficacy. It delineates future trends in the dynamics of such a dynamic profession, leading to innovation at every step. Good examples of such successful drug discoveries serve to well illustrate practical examples and the nature of change brought about by innovation in pharmaceutical research.

  • Conclusion and Future Prospects on Drug Discovery

    by Talamanchi Balakrishna, Raveesha Peeriga, Krishnaveni Manubolu, K. N. V. Chenchu Lakshmi, Miriyala Preethika, Nimmagadda Sai Sruthi, Afsar Shaik

    In this chapter, we summarize recent progress in drug discovery and assess its implications for future research and development. The final section summarizes recent key findings from high-throughput screening (HTS), biomarker identification and personalized medicine. Moreover, it identifies the challenges encountered, like high costs, extended development cycles and both regulatory and commercial hurdles. Emerging trends in drug discovery, such as artificial intelligence (AI), genomic integration, and new therapeutic modalities, are explored as future prospects. By highlighting the successes, the challenges that persist, and the innovations that might alter the face of drug development, this analysis covers the full version of the progress to date. Results highlight a need for sustained interdisciplinary partnerships and continued investment in state-of-the-art technologies to overcome current constraints and progress discovery toward new, effective therapies.


  • Emerging Technologies and Their Trends

    by Talamanchi Balakrishna, Venkateswara Rao Javvaji, Raveesha Peeriga, Sonti Lavanya, Avisa Indira, Suchitra Monapati

    One of the hottest areas that opens up is at the junction of CRISPR technology and microbiome-based therapeutics in the rapidly growing horizon of medical research. This ranges from some genetic diseases to chronic diseases influenced by microbial communities and, therefore, holds much promise therapeutically with mechanisms of precision gene editing mediated by CRISPR-Cas9 and manipulation of the microbiome. This new technology has broken the barriers of precision genome alteration with unprecedented accuracy and efficiency for mankind, and this is something that the CRISPR-Cas9 technology goes beyond. The potential of CRISPR in terms of altering specific DNA sequences looks promising regarding the possibility of making cellular processes more effective, correcting genetic defects responsible for inherited diseases, and advancing discoveries on new medicines. Billions of bacteria live in and on part of the human body. As such, the microbiome is the central aspect of disease states and general health. Technological advances in the omics field-transcriptomics, proteomics, metabolomics, and genomes make it currently possible to offer highly detailed molecular medicine.

  • Open Access

    Natural and Synthetic Polymer-Based Transdermal Patch Formulation for Bosentan: Development and in vitro Evaluation

    by Balakrishna Talamanchi, Lakshman Kumar Dogiparthi, Bala Sree Sanjeevi Pusala, Roshni Patan, Vamsi Abhiram Yadlapalli, Vinay Simhadri, Shahid Hussain Shaik, Yasaswini Vakkalagadda

    Introduction The goal of this study was to develop and evaluate Bosentan transdermal patches for the treatment of Pulmonary Arterial Hypertension (PAH), which is defined as an abnormally high blood pressure in the arteries that supply blood to the lungs, in patients aged three and up. Patients with PAH may find that bosentan aids their exercise performance and slows the worsening of their symptoms.Materials and Methods Using the solvent casting method, Bosentan transdermal patches were made with karaya gum and polyethylene oxide as polymers, PEG 600 as plasticizers and propylene glycol as a permeation enhancer. Folding endurance values for the manufactured Bosentan transdermal patches ranged from 95 to 100, indicating that the patches exhibited good elasticity and flexibility. -p f.Results and Discussion The optimized formulation B-10 released 94.77% of the drug for up to 12 hr, according to the drug release trial. Studies using Fourier infrared spectroscopy and differential scanning calorimetry were carried out on the pure drug, polymers and optimised formulation B-10. The results showed that the drug and polymers did not interact with one another. There were no surface cracks or defects in the patches when SEM examination was performed on the pure drug and optimised formulation B-10.


  • A Schematic Review on Prevalence of and Society’s Reaction to Child Sexual Abuse

    by Balakrishna Talamanchi, Mohan Gandhi Bonthu, Pavani Gayatri Alluri, Avisa Indira